Chinese Pharma Experts Discuss Innovative Drugs’ Full Chain From R&D to MarketYicai·Aug 6 at 01:33 AM09995-1.33%688192-3.28%
‘Systemic leap’: China’s drug innovation push yields bumper cropSCMP·Jul 20 at 06:03 PM02171+3.40%688192-3.28%
Institutional Investors Net Buy Kailan Ying, Giant Network, Aerospace Electronics on July 15CoinLive·Jul 15 at 07:13 AM601698-5.28%688192-3.28%
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drugPharmaceutical Technology·Jul 14 at 09:14 AMAZNAZN+2.05%
02:00 ETDizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovyprnewswire·Jul 14 at 01:01 AM688192-3.28%AZN+2.05%
20:09 ETDizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026prnewswire·May 30 at 07:10 PM688192-3.28%
08:52 ETDizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancerprnewswire·May 29 at 07:53 AM688192-3.28%
06:40 ETDizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancerprnewswire·May 27 at 05:42 AM688192-3.28%
12:45 ETDizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026prnewswire·Apr 21 at 11:47 AM688192-3.28%
